NEWSFLOW

views

On developer of “compounds to tackle obesity, cardiovascular disease and diabetes”, OptiBiotix Health (OPTI) we’ve previously noted ‘some delays in delivery but a sales recovery Buy’ – including with “product launches by Apollo Pharmacies in India and restocking by some partners with sales normalising… as in previous years, there was no contribution in this period from licence or royalty payments which tend to be received in the second half”. We’ve since again spoken to CEO Steve O'Hara.

views

OptiBiotix Health (OPTI), a developer of “compounds to tackle obesity, cardiovascular disease and diabetes”, has recently provided an update presentation on its commercial strategy and future plans. At a current 19p, the shares are at least up from 16.5p lows last month but remain well down from above 30p as recently as August and 46p at the start of this year and we’ve spoken to CEO Steve O'Hara.

views

OptiBiotix Health (OPTI) has announced the opening of an online shop on Tmall.com for its Go-Figure products and that it has launched GoFigure shakes containing patented weight management aid SlimBiome on Tmall China. What of this and of a share price edging up to 19p to buy?

views

OptiBiotix Health (OPTI) has announced Nahdi Medical Co has received approval from the Saudi Food and Drug Authority for GoFigure shakes and bars and that it has received the first purchase order from Nahdi.

NEWSFLOW

views

Previously writing on OptiBiotix Health (OPTI), earlier this month we noted prior delays in delivery from larger deals but that orders are already coming through and being booked as second half sales. Now some clear evidence of this with an announcement that the company’s GoFigure meal replacement shakes and powdered beverage shots have now been officially launched by India's Apollo Hospitals & Pharmacies.

NEWSFLOW

views

OptiBiotix Health (OPTI) has announced what it states is an important extension of its commercial experience and reach in the Asia Pacific region – with an agreement with Nutraconnect Pte., Ltd to develop and implement a market strategy there.

views

OptiBiotix Health (OPTI) has announced that it now expects half-year sales in its new structure to be materially lower than expected and, though it expects sales normalising in the second half and healthy growth next year, the current year is to now be “insufficient to make up the H1 deficit”. We profusely apologise for the short-term disappointment though, having spoken to the company, what to do now with the shares down at 20p to buy, a £17.6 million market cap?